Gene Solutions Showcases MRD and Multi-Omics Innovations at SSO ASM 2025

At the Singapore Society of Oncology Annual Scientific Meeting 2025 (SSO ASM 2025), held on October 15, 2025, Gene Solutions unveiled significant advancements in Molecular Residual Disease (MRD) and multi-omics technologies. This presentation highlighted a shift in cancer care from reactive to proactive approaches, emphasizing the potential of these innovations to enhance precision oncology across the Asia-Pacific region.

The symposium, titled “Advancing Precision Oncology: MRD and Multi-Omics in Solid Tumors,” attracted leading oncologists and experts in molecular biology. Attendees explored how circulating tumor DNA (ctDNA) MRD and multi-omics technologies are transforming the capabilities of clinicians and researchers in detecting and monitoring cancer.

Key Insights into MRD and Multi-Omics

MRD assays utilize ctDNA analysis from blood samples to monitor cancer at a molecular level. During the event, experts discussed several promising applications of this method. For instance, the ability to detect minimal residual disease can lead to more timely interventions, potentially improving patient outcomes.

Gene Solutions employs a unique scientific approach, integrating DNA, RNA, and AI-enhanced multi-omics signals to provide comprehensive tumor profiling. This methodology enhances ctDNA sensitivity, facilitates the detection of complex gene fusions, and predicts primary tumor locations, thereby enabling more personalized treatment decisions.

Recent studies published in JCO Oncology Advances and Nature’s npj Breast Cancer underscore the effectiveness of ctDNA-based MRD testing. These studies demonstrate the potential of this technology to predict early recurrences of cancer and contribute to cost-effective monitoring strategies in real-world settings.

Fostering Collaborative Efforts

Ida Deleskog Lindstroem, Global Medical Affairs Director at Gene Solutions, emphasized the importance of collaboration in advancing these technologies. She stated, “Molecular residual disease (MRD) and multi-omics platforms show promise in advancing precision oncology by enabling clinicians to detect cancer recurrence earlier and tailor treatments more effectively. We invite oncologists, researchers, and healthcare partners across Asia-Pacific to collaborate in advancing these technologies, fostering data-driven, personalized care that aims to improve patient outcomes across diverse healthcare systems.”

With a CAP-accredited laboratory located in Singapore and a network of global operations, Gene Solutions is committed to promoting scientific collaboration to enhance genomic research and precision oncology throughout the Asia-Pacific region.

About Gene Solutions: The company is a multinational biotechnology organization recognized for its innovation in genetic testing and research across the Asia-Pacific. Utilizing Next-Generation Sequencing (NGS) and Artificial Intelligence, Gene Solutions offers a comprehensive portfolio of advanced solutions and has delivered over two million genetic tests. Their contributions to advancing precision medicine include proprietary research, CAP-accredited laboratories, and active participation in clinical studies and regional collaborations.

For further information about the symposium and Gene Solutions’ initiatives, visit: Gene Solutions News.